0.384  0 (0%)		02-17 16:00
Open: 0.3724 High: 0.39 Volume: 145,041		Pre. Close: 0.3839 Low: 0.3613 Market Cap: 0(M)

Short term
Mid term
Targets	6-month :	0.81	1-year :	0.95
Resists	First :	0.69	Second :	0.81
Pivot price	0.66
Supports	First :	0.57	Second :	0.5
MAs	MA(5) :	0.66	MA(20) :	0.64
	MA(100) :	0.42	MA(250) :	0.36
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	88.3	D(3) :	82.2
RSI	RSI(14): 61.8
52-week	High :	0.69	Low :	0.19

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ ISR ] has closed below upper band by 25.7%. Bollinger Bands are 32.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	0.69 - 0.7	0.7 - 0.7
Low:	0.64 - 0.64	0.64 - 0.64
Close:	0.68 - 0.69	0.69 - 0.7

Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. Isoray, Inc. was founded in 1998 and is based in Richland, Washington.

Wed, 08 Feb 2023
Medtech companies merge to form Perspective Therapeutics - Corridor Business Journal

Mon, 06 Feb 2023
Isoray Completes Merger with Viewpoint Molecular Targeting to Advance New Treatment Paradigm in Targeted Precision Oncology Medicine - Business Wire

Tue, 18 Oct 2022
Isoray Medical, Inc. and Viewpoint Molecular Targeting, Inc. Announce Investor Webcast on October 19, 2022 at 4:15 p.m. EDT - Business Wire

Mon, 14 Jun 2021
Isoray raises $50M to expand Cesium-131 cancer treatments - Tri-Cities Area Journal of Business

Thu, 28 Jan 2021
7 Penny Stock Bubbles That Are About to Burst - InvestorPlace

Wed, 28 Sep 2016
IsoRay, Inc. Announces Launch of Newly Redesigned Patient and Clinician Focused Corporate Website - PR Newswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: AMEX
Sector: Healthcare
Industry: Medical - Devices
Shares Out	142 (M)
Shares Float	140 (M)
Held by Insiders	0.8 (%)
Held by Institutions	11.2 (%)
Shares Short	1,150 (K)
Shares Short P.Month	1,580 (K)

EPS	-0.04
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0.05
Book Value (p.s.)	0.46
Profit Margin	-48.1 %
Operating Margin	-48.9 %
Return on Assets (ttm)	-8.2 %
Return on Equity (ttm)	-13.9 %
Qtrly Rev. Growth	7.5 %
Gross Profit (p.s.)	0.03
Sales Per Share	0.07
EBITDA (p.s.)	-0.04
Qtrly Earnings Growth	0 %
Operating Cash Flow	-5 (M)
Levered Free Cash Flow	-3 (M)

PE Ratio	-17.25
PEG Ratio	0
Price to Book value	1.49
Price to Sales	9.56
Price to Cash Flow	-21.38

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.